Companion diagnostics in cancer care: Collaboration is key for continued innovation

The value of companion diagnostics should not be underestimated in the future of cancer care and precision medicine.

The concept of companion diagnostics is not new. The first companion diagnostic was approved more than 25 years ago when an optimized immunohistochemistry assay was developed during trials for the breast cancer drug Herceptin (trastuzumab).1 The assay detected HER2 overexpression in tumors, meaning the patient population most likely to respond to the drug could be identified. The success of this innovative approach paved the way for a drug and diagnostic co-development model where a predictive biomarker assay is used to select patients most likely to respond to treatment.1

Healthcare Transformers spoke to Trent Landon, Robert Loberg, and Helen Wu about why companion diagnostics are so important in cancer care, and how diagnostic and pharmaceutical partners can work together to innovate in this space.

Read on healthcaretransformers.com

How to Maintain Good Ear Hygiene Without Damaging Your Ears

Taking care of your ears is just as important as brushing your teeth or washing your face, but it’s often overlooked. Most people don’t think about ear hygiene until they experience problems like …